Researchers say if their results are confirmed through further study they are optimistic the approach could be used to treat chronic infections for the first time.

Company to submit sNDA around the end of 1Q 2025 seeking traditional approval of FILSPARI® (sparsentan) for FSGS Net product sales of FILSPARI totaled $50 million in 4Q 2024; $132 million for full yea ...

Health researchers working with DENT Neurologic Institute, Jamaica pharmaceutical company to increase global clinical research.

The article highlights the potentially game-changing approach of the Company towards treating Alzheimer’s Disease, based on technology developed at Rutgers by Dr. Luciano D’Adamio, PhD, MD, New Jersey ...

BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, today announced that it has garnered the "Cancer Immunology Solution of the Year" award in the fourth annual ...

Zixin is a biotechnology company focused on the sweet potato industry, integrating seedling breeding, planting, product ...

Charles River's balance sheet is sound, with its revenue cyclicality and operating leverage each possessing a medium rating. The company ended 2024 with about $195 million in cash, and it recorded a ...

A0794644 PORTLAND, IL, UNITED STATES, February 19, 2025 /EINPresswire / -- According to the report, the global animal mode ...

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the ...

Sunzen Group Bhd is disposing of its loss-making animal health subsidiaries, Sunzen Corp Sdn Bhd (SCSB) and Sunzen ...

The southern stingrays were among the most plentiful fish, though it took some effort to see them because of their camouflage ...